Daxor Corporation
Last updated September 27, 2026
Organization details
- Legal name
- Daxor Corporation
- Ownership
- Public
- Status
- Active
- Jurisdiction of incorporation
- New York
- Headquarters city
- OAK Ridge
- Headquarters state / province
- Tennessee
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- DXR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000027367
- EIN
- 13-2682108
Board of directors
-
Caleb DesRosiers · DirectorSince 2023
-
Edward Feuer · DirectorSince 2023
-
Henry D. Cremisi · DirectorSince 2023
-
James A. Lombard · DirectorSince 2023
-
Jonathan Adam Feldschuh · Director · Chief Scientific OfficerSince 2023
-
Joy S. Goudie · DirectorSince 2023
-
Michael Richard Feldschuh · Director · Chief Executive OfficerSince 2023
Chief executives
Michael Richard Feldschuh
· Chairman, President & CEO
Dates unknown
Director election results
Annual meeting of June 23, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
92.5%
-
92.6%
-
99.9%
-
99.9%
-
99.9%
-
99.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $18,970
- 7 purchases by 4 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 28, 2026 | Jefferies John Officer (Chief Medical Officer) | Grant or award | +2,451 | — | — |
| Jun 23, 2026 | Robert J. Michel Officer (Chief Financial Officer) | Grant or award | +12,000 | — | — |
| Jun 23, 2026 | Michael Richard Feldschuh Director, Officer (Chief Executive Officer) | Grant or award | +30,000 | — | — |
| Jun 23, 2026 | Jonathan Adam Feldschuh Director, Officer (Chief Scientific Officer) | Grant or award | +25,000 | — | — |
| Apr 8, 2026 | Michael Richard Feldschuh Director, Officer (Chief Executive Officer) | Open-market purchase | +1,000 | $9.07 | $9,070 |
| Mar 31, 2026 | Robert J. Michel Officer (Chief Financial Officer) | Open-market purchase | +1,000 | $9.90 | $9,900 |
| Mar 20, 2026 | Jefferies John Officer (Chief Medical Officer) | Open-market purchase | +3,656 | — | — |
| Mar 20, 2026 | Jefferies John Officer (Chief Medical Officer) | Open-market purchase | +2,285 | — | — |
| Dec 9, 2025 | Robert J. Michel Officer (Chief Financial Officer) | Open-market purchase | +3,000 | — | — |
| Dec 9, 2025 | Jonathan Adam Feldschuh Director, Officer (Chief Scientific Officer) | Open-market purchase | +18,000 | — | — |
| Nov 12, 2025 | Jefferies John Officer (Chief Medical Officer) | Open-market purchase | +2,344 | — | — |
| Apr 4, 2025 | Michael Richard Feldschuh Director, Officer (Chief Executive Officer) | Open-market purchase | +2,063 | $7.89 | $16,277 |
| Mar 10, 2025 | Robert J. Michel Officer (Chief Financial Officer) | Open-market purchase | +1,000 | $8.00 | $8,000 |
| Mar 10, 2025 | Michael Richard Feldschuh Director, Officer (Chief Executive Officer) | Open-market purchase | +3,360 | $7.68 | $25,805 |
| Dec 6, 2024 | Jonathan Adam Feldschuh Director, Officer (Chief Scientific Officer) | Open-market purchase | +32,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.